Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol (NCT03997370)

🧪 Interventions in This Study

• Carboplatin (DRUG)
• Iohexol (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (189 Sites)

Showing the first 25 of 189 sites.

• University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• Mercy Hospital Fort Smith — Fort Smith, Arkansas
• CARTI Cancer Center — Little Rock, Arkansas
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• UC San Diego Health System - Encinitas — Encinitas, California
• UC San Diego Moores Cancer Center — La Jolla, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• UC San Diego Medical Center - Hillcrest — San Diego, California
• UCHealth University of Colorado Hospital — Aurora, Colorado
• Poudre Valley Hospital — Fort Collins, Colorado
• Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
• UCHealth Greeley Hospital — Greeley, Colorado
• Medical Center of the Rockies — Loveland, Colorado
• Hartford Hospital — Hartford, Connecticut
• The Hospital of Central Connecticut — New Britain, Connecticut
• Sibley Memorial Hospital — Washington D.C., District of Columbia
• Emory University Hospital Midtown — Atlanta, Georgia
• Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
• Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah, Georgia
• Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
• Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
• Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
• Walter Knox Memorial Hospital — Emmett, Idaho

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Malignant Solid Neoplasm

• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) — Philadelphia, Pennsylvania
• Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors — Birmingham, Alabama
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) — Philadelphia, Pennsylvania
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial — Birmingham, Alabama
• Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial — Bethesda, Maryland
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) — Philadelphia, Pennsylvania

Explore by condition: All Malignant Solid Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.